Antineoplastic Immune Cell

Phase 1Biologic

Antineoplastic Immune Cell is one of 14 biologic programs targeting Advanced Lung Non-Small Cell Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Lung Non-Small Cell CarcinomaActive, not recruiting

Advanced Lung Non-Small Cell CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Advanced Lung Non-Small Cell Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

2 2

Abraxane

Bristol-Myers Squibb

Phase 3

1 3

Taxol

Teva

Phase 3

1 4

Paraplatin

AAvyxa

Phase 3

1 5

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

1 6

Alimta

SShawn Eagle

Phase 3

1 7

Tecentriq

Roche

Phase 2

2 8

Tagrisso

AstraZeneca

Phase 2

2 9

Lumakras

Amgen

Phase 2

1 10

Krazati

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Advanced Lung Non-Small Cell Carcinoma

NCT05334329

Clinical

Trials by Indication[1]

Advanced Lung Non-Small Cell Carcinoma1 trial

Phase 1 Trial of Umbilical Cord Blood Natural Killer Cells (CB-NK) Expressing Soluble IL-15 (sIL-15) and PD-L1 +/- Atezolizumab in Non-Small Cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors

Active, not recruiting·UUniversity of California, Irvine·Phase 1·NCT05334329·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antineoplastic Immune Cell. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antineoplastic Immune Cell compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antineoplastic Immune Cell. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Irvine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity of California, Irvine

Antineoplastic Immune Cell

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Advanced Lung Non-Small Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News